Quanterix Corporation (QTRX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Quanterix Announces Commercialization of p-Tau 217 Test Kit

Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly Quanterix Corporation (NASDAQ: QTRX), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Quanterix to Participate at the Morgan Stanley 22nd Annual Global Healthcare Conference

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Jeffrey Elliott Appointed to Quanterix’s Board of Directors

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report